Platelet Aggregability in Patients with Hypertension Treated with Angiotensin II Type 1 Receptor Blockers
Authors:
Open Access
- 1 January 2007
- journal article
- clinical trial
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 14 (1) , 31-35
Abstract
Aim: Cardiovascular events associated with hypertension often involve thrombosis. Increased platelet activity is one of the risk factors of cardiovascular diseases. Antithrombotic properties of antihypertensive agents are not fully characterized. Angiotensin II type 1 receptor blockers (ARBs) are widely used for the treatment of hypertension. Some ARBs can provoke antiaggregatory effects on platelets in vitro. Whether ARBs can inhibit platelet aggregation was tested in hypertensive patients in vivo. Methods: Platelet aggregation was assessed by the highly sensitive particle counting method using laser-light scattering. Results: Large platelet aggregation induced by adenosine diphosphate (ADP, 3 µM) was 2.6±0.4 (×10&sup7;) (SE) in hypertensive patients treated with losartan (72±3 years old, n=10) while it was 3.9±0.6 in hypertensive patients treated with candesartan (70±5 years old, n=6; p=0.056). Large platelet aggregation induced by thromboxane A2 receptor agonist, U46619 (10 µM), was 2.8±0.5 (×10&sup7;) in hypertensive patients treated with losartan while it was 5.1±0.9 in hypertensive patients treated with candesartan (p=0.033). Clinical characteristics including the control of blood pressure did not differ between the two groups (losartan 136±5/73±3 mmHg vs. candesartan 135±4/76±5). Conclusion: Thus, losartan may have the possibility to inhibit platelet activation in patients with hypertension independent of blood pressure reduction. Antiaggregatory properties may be independent of angiotensin II type 1 receptor or of antihypertensive actions. The favorable effects of losartan on reduction of adverse cardiovascular events among hypertensive patients may be at least partly mediated by inhibition of platelet activation.Keywords
This publication has 23 references indexed in Scilit:
- Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus.Journal of Atherosclerosis and Thrombosis, 2006
- Platelet indexes in relation to target organ damage in high-risk hypertensive patientsJACC, 2004
- Effects of Severe Hypertension on Endothelial and Platelet MicroparticlesHypertension, 2003
- Angiotensin II Receptor–Independent Antiinflammatory and Antiaggregatory Properties of LosartanCirculation Research, 2002
- A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertensionAmerican Journal of Hypertension, 2001
- Effect of Temocapril Hydrochloride on Serum Lipid Levels in Patients with Hypertensive Type 2 Diabetes MellitusJournal of Atherosclerosis and Thrombosis, 2001
- Effect of losartan on human platelet activationJournal Of Hypertension, 1999
- Detection of Platelet Aggregates with a Particle Counting Method Using Light ScatteringAnalytical Biochemistry, 1994
- The electronic aggregometer: A novel device for assessing platelet behavior in bloodJournal of Pharmacological Methods, 1980
- Aggregation of Blood Platelets by Adenosine Diphosphate and its ReversalNature, 1962